TABLE 1.
Baseline patient and colonoscopy characteristics of the study population (n=420)
| Patient characteristic | |
|---|---|
| Age, years mean ± SD | 58.7±8.3 |
| Female sex | 192 (45.7) |
| Preferred contact method | |
| 267 (63.6) | |
| Telephone | 153 (36.4) |
| Comorbidities | 95 (22.6) |
| High-risk medications | 89 (21.2) |
| Symptoms in the 30 days before colonoscopy (n=418) | |
| Any symptom | 237 (56.4) |
| Abdominal pain | 73 (17.4) |
| Bloating | 107 (25.5) |
| Diarrhea | 56 (13.3) |
| Constipation | 81 (19.3) |
| Nausea/vomiting | 32 (7.6) |
| Blood in stools | 39 (9.3) |
| Rectal pain | 40 (9.5) |
| Headache/migraine | 77 (18.3) |
| Other | 57 (13.6) |
| Ethnic background | |
| White | 367 (87.4) |
| Nonwhite | 53 (12.6) |
| Endoscopy characteristics | |
|
| |
| Colonoscopy indication | |
| Screening | 200 (47.6) |
| Not screening | 220 (52.4) |
| Fentanyl dose, μg, mean ± SD | 83.6±35.9 |
| Midazolam* dose, mg, mean ± SD | 3.1±1.3 |
| Endoscopy duration, min, mean ± SD | 21.7±7.8 |
| Trainee participation | 30 (7.2) |
| Method of colon insufflation | |
| Air | 100 (24) |
| Carbon dioxide | 320 (76) |
| Cecal intubation, %, mean ± SD | 96±0.2 |
| Preparation quality | |
| Excellent or good | 372 (88.6) |
| Poor or fair | 44 (10.5) |
Data presented as n (%) unless otherwise indicated.
*
Versed (Roche, USA)